Please list your purchase and sale transaction(s) in the Esperion Therapeutics, Inc. (NASDAQ: ESPR) security that is subject of this action between August 18, 2015 and September 28, 2015:
You may also contact James Maro, Jr., Esq. toll free at 844.887.9500, or you may submit your information via email at firstname.lastname@example.org, or you may click here to print a PDF of this form.
On January 12, 2016, the initial complaint in this securities class action was filed against Esperion Therapeutics, Inc. (“Esperion” or the “Company”) and Esperion’s CEO, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act. Lead Plaintiff alleges that defendants made false and misleading statements by misrepresenting the future prospects for Esperion’s drug ETC-1002. Defendants’ conduct artificially inflated the price of Esperion common stock and operated as a fraud on the Class.
On June 6, 2019, Lead Plaintiff filed a Motion for Class Certification. That Class was certified by the Court on May 31, 2020. The Court certified the Class as: all persons who purchased or otherwise acquired the common stock of Esperion Therapeutics, Inc. between August 18, 2015 and September 28, 2015 (inclusive) and were damaged thereby.
Current Status of Case:
Defendants filed a Motion for Summary Judgement on September 15, 2020. That Motion is currently being briefed by the parties. This action is still ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453; or via e-mail at email@example.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.